Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
Status:
Completed
Trial end date:
1998-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Demonstrate the safety and efficacy of dihematoporphyrin derivative (DHP) in laser
photodynamic therapy (PDT) in patients with corneal neovascularization.
II. Document the histopathologic mechanism of action in selected patients undergoing
penetrating keratoplasty following PDT therapy for corneal neovascularization.
III. Facilitate FDA product approval of DHP as a photosensitizing agent for laser treatment
in these patients.
IV. Explore the use of this photosensitizer for ocular and cutaneous basal cell and squamous
cell carcinoma.